Highest-materiality recent filing
Directors Paul L. Berns, Matthew Fust, David Piacquad elected with ~126M, ~125M, ~127M votes for, respectively; ~25M broker non-votes.
Neumora Q1 net loss $53.5M, cash $147M; navacaprant data on track for Q2 2026
Net loss of $53.5M for Q1 2026, improved from $68.0M in Q1 2025.
Cash $182.5M; FY net loss $236.9M; R&D $176.1M, G&A $60.1M; cash runway into Q3 2027.
Presentation dated February 2026 made available for Guggenheim Emerging Outlook: Biotech Summit.
Corporate presentation made available under Item 7.01, not filed for SEC purposes.
NMRA-511 Phase 1b shows clinically meaningful effect in AD agitation; navacaprant readout in Q2 2026
NMRA-511 Phase 1b: 15.7-point mean CMAI reduction, no somnolence/sedation; plan higher doses and Phase 2/3 in 2026
K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share
K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.
Neumora Q3 net loss $56.8M; cash $171.5M; pipeline updates on NMRA-215, M4 PAMs, NMRA-511
Net loss of $56.8M for Q3 2025 vs $72.5M in Q3 2024; R&D expense down to $40.5M from $60.6M.
Neumora reports NMRA-215 preclinical data: up to 19% monotherapy weight loss, 26% with semaglutide
NMRA-215 showed class-leading 19% weight loss as monotherapy with semaglutide-like induction in DIO mice.
Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical
Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.
Neumora Q2 net loss $52.7M, cash $217.6M; advances NMRA-861 Phase 1, obesity lead for NMRA-215
Cash, equivalents and marketable securities of $217.6M as of June 30, 2025; expected to fund operations into 2027.
Elected Alaa Halawa (105,795,914 votes for) and Maykin Ho (114,262,481 votes for) as Class II directors.
Neumora receives Nasdaq minimum bid price deficiency notice; has until Nov 10, 2025 to cure
Nasdaq notified Neumora on May 14, 2025 that its stock failed to meet the $1.00 minimum bid price requirement.
Neumora Q1 net loss $68M, secures $125M venture debt; navacaprant Ph3 data in 2026
Net loss $68.0M in Q1 2025, up from $53.7M in Q1 2024; R&D expense $52.2M (incl. $6.3M final Amgen costs).
Neumora revises stock option repricing to use closing price on May 28, 2025 annual meeting date
Originally repriced using Feb 13, 2025 closing price; revised on Apr 7, 2025 to use closing price on scheduled annual meeting date (May 28, 2025).
Neumora modifies KOASTAL-2/-3 MDD studies, delays data to 2026; R&D head departs
KOASTAL-2/-3 paused, resume March 2025; topline data from KOASTAL-3 in Q1 2026 and -2 in Q2 2026.
Neumora Therapeutics appoints Paul Berns as Chairman & CEO, Gosebruch exits
Henry Gosebruch separates as CEO; receives 12-month base salary, 2025 target bonus, 18-month COBRA, 2024 bonus, and 12-month option exercise period.
Founder Berns becomes CEO as Gosebruch departs; option repricing approved
Paul L. Berns transitions from executive chair to CEO & chairman, effective Feb 14, 2025.
Corporate presentation made available for J.P. Morgan Healthcare Conference on Jan 13, 2025.
Neumora's Phase 3 KOASTAL-1 study of navacaprant fails primary endpoint in MDD
Primary endpoint MADRS total score change at Week 6: -12.5 for both navacaprant and placebo (p=0.993); no statistical improvement.
Neumora Q3 net loss $72.5M; cash $341.3M; Ph3 MDD data around end-2024
Cash and marketable securities $341.3M; operations funded into mid-2026.
Neumora Q2 net loss $58.7M; Phase 3 MDD data on track for Q4 2024
Cash $371.6M as of June 30, 2024, expected to fund operations into 2026.
Neumora stockholders elect Gosebruch and Burow as Class I directors, ratify EY as auditor
Henry O. Gosebruch elected with 88,190,874 votes for, 2,313,739 withheld, and 12,544,469 broker non-votes.
Net loss of $53.7M in Q1 2024 vs $35.6M in Q1 2023; R&D expense $45.8M, G&A $14.3M.
Neumora's NMRA-266 Phase 1 placed on clinical hold by FDA after rabbit convulsion data
FDA placed clinical hold on NMRA-266 Phase 1 trial due to preclinical convulsions in rabbits.
the Company has entered into a Separation Agreement, dated February 14, 2025, with Henry Gosebruch, the Company’s former President and Chief Executive Officer
an Executive Employment Agreement, effective as of February 14, 2025, with Paul L. Berns, as the Company’s Chairman and Chief Executive Officer
Joshua Pinto, Ph.D. will transition from the role of Chief Financial Officer to President
Henry Gosebruch will depart the Company and no longer serve as President, Chief Executive Officer or a member of the Board.
Carol Suh will transition from the role of Chief Operating Officer to Chief Strategy Officer
Bill Aurora, Pharm.D. will transition from the role of Chief Strategy Officer to Chief Operating and Development Officer
Jason Duncan will serve as Chief Legal and Administrative Officer
Kaya Pai Panandiker will depart the Company and no longer serve as Chief Commercial Officer.
Michael Milligan will serve as Chief Financial Officer in addition to his current role as principal accounting officer
Paul L. Berns, the Company’s Co-Founder and Executive Chairman of its Board of Directors (the “Board”), will transition to the roles of Chief Executive Officer and Chairman of the Board
Max materiality 0.85 · Median 0.65 · Most common event other_material